Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced it will host a virtual investor event on Erasca pipeline updates on Monday, June 5, 2023, at 4:30 PM ET.
The Erasca leadership team will discuss its pipeline targeting RAS/MAPK pathway-driven cancers, with a focus on ERAS-007, a potentially best-in-class ERK1/2 inhibitor in Phase 1b/2 clinical development for the treatment of patients with RAS/MAPK pathway-altered solid tumors.
A live question and answer session will follow the formal presentation. To register for the event, please click here.
Source: Erasca, Inc.
Solutions Showcase Session
Transforming GRC and Cyber Security with AI